16. Chandrasoma PT. Pathologic evaluation of imaging directed stereotactic biopsy materials. In: 
Apuzzo MLJ, ed. Malignant Cerebral Glioma. Park Ridge, 111: American Association of Neurological 
Surgeons, 1990; chapter 9:129-140 
17. North RJ, Bursuker I. Generation and decay of the immune response toa progressive fibrosarcoma I. 
LY-1+2- suppressor T cells down-regulate the generation of LY-1-2+ effector T Cells. J Exp Med 1984; 
159:1295-311 
18. Webb S. Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a 
consequence of immunity. Cell 1990; 63:1249-56 
19. Roszman T, Elliot L, Brooks W. Modulation of T-cell function by gliomas. Immunology Today 1991; 
12:370-374 
20. Couldwell WT, Mitchell MS, Mazumder A, Apuzzo MLJ. Immunology and immunotherapy of 
intrinsic glial tumors. In: Apuzzo MLJ, ed. Malignant Cerebral Glioma. Park Ridge, 111: American 
Association of Neurological Surgeons, 1990; chapter 4:41-62 
21. Brooks WH, Latta RB, Mahaley MS. Immunobiology of primary intracranial tumors. J Neurosurg 
1981;54:331-337 
22. Fontana A, Hengartner H, deTribolet N, Weber E. Glioblastoma cells release interleukin 1 and 
factors inhibiting interleukin-2 mediated effects. J Immunol 1984; 132:1837-44 
23. Wrann M, Bodmer S, deMartin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A. T cell 
suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming 
growth factor beta. EMBO Joumall987; 6:1633-6 
24. Couldwell WT, Dore-Duffy P, Apuzzo MLJ, Antel JP. Malignant glioma modulation of immune 
function: relative contribution of different soluble factors. J Neuroimmunology 1991; 31:89-96 
25. Mapstone TB. Expression of platelet-derived growth factor and transforming growth factor and 
their correlation with cellular morphology in glial tumors. J Neurosurg 1991; 75(3):447-51 
26. Sawamura Y, deTribolet N. Immunotherapy of brain tumors. J Neurosurgical Sciences 1990; 34:265-78 
27. Merchant RE, Grant AJ, Merchant LH, Young HF. Adoptive immunotherapy for recurrent 
glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. 
Cancer 1988; 62:665-71 
28. Apuzzo MLJ, Mitchell MS. Immunological aspects of intrinsic glial tumors. J Neurosurg 1981;55:1-18 
29. Mahaley MS Jr, Bigner DD, Dudka LF,Wilds PR, Williams DH, Bouldin TW, Whitaker JN, Bynum 
JM. Immunobiology of primary intracranial tumors. Part 7: active immunization of patients with 
anaplastic human glioma cells: a pilot study. J Neurosurg 1983; 59:201-7 
30. Trojan J, Johsnon TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat 
glioblastoma by immunogenic Cc6 cells expressing antisense IGF-I RNA. Science 1993; 259:94-97 
31. Sandberg AC, Engberg C, Lake M, von Holst H, Sara VR. The expression of insulin-like growth 
factor I and insulin-like growth factor II genes in the human fetal and adult brain and in glioma. 
Neuroscience Letters 1988; 93:114-119 
32. Prisell P, Persson L, Boethius J, Sara VR. Somatomedins in tumor cyst fluid, cerebrospinal fluid and 
tumor cytosol in patients with glial tumors. Acta Neurochir 1987; 89:48-52 
[146] 
Recombinant DNA Research, Volume 18 
